Cargando…
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
Several treatments are currently available for relapsing-remitting multiple sclerosis. Among them, interferon (IFN) beta remains a valid treatment approach because of its good benefit/risk profile. Due to the need for frequent administration (weekly, at a minimum), the use of IFN beta is limited by...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431469/ https://www.ncbi.nlm.nih.gov/pubmed/26056458 http://dx.doi.org/10.2147/TCRM.S69123 |